Analytical Data
-
Gene name
ANXA11
- Application
-
Alternative Names
ANX-A11; ANX11; CAP50; 56 kDa autoantigen; Calcyclin-associated annexin 50
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P50995
-
Expression Region
Met1~Asp505
-
Molecular Weight
58.1kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ANXA11 (Annexin A11) is a member of the annexin family of proteins, known for their calcium-dependent binding to phospholipids and involvement in various cellular processes, including membrane trafficking, cell signaling, and apoptosis. Recent studies have highlighted ANXA11's critical role in human pathologies, particularly its association with diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Moreover, ANXA11 has been identified as a key player in the pathological aggregation of proteins, suggesting its involvement in neurodegenerative processes. The interest in recombinant ANXA11 proteins stems from the need to better understand its functional mechanisms and pathological implications. By producing recombinant ANXA11 in vitro, researchers aim to dissect its structural characteristics and assess its interactions with other cellular molecules. This research can potentially unveil novel therapeutic targets for diseases linked to ANXA11 dysfunction. Additionally, studying recombinant ANXA11 allows for the exploration of its potential as a biomarker in neurodegenerative disorders, paving the way for early diagnosis and intervention strategies. Overall, the investigation of ANXA11 recombinant proteins is crucial for advancing our understanding of its biological significance and developing targeted therapies against related diseases.
